PTP4A3 and acute myeloid leukemia: A significantly lower cell viability percentage was recorded in samples subjected to combined treatment as compared to samples treated with single agent VS-5844 or ICG-001 in primary AML cells with high PRL-3, but not in samples with low PRL-3.